Literature DB >> 31221552

IFN-γ: A cytokine at the right time, is in the right place.

J Daniel Burke1, Howard A Young2.   

Abstract

Interferon gamma has long been studied as a critical mediator of tumor immunity. In recent years, the complexity of cellular interactions that take place in the tumor microenvironment has become better appreciated in the context of immunotherapy. While checkpoint inhibitors have dramatically improved remission rates in cancer treatment, IFN-γ and related effectors continue to be identified as strong predictors of treatment success. In this review, we provide an overview of the multiple immunosuppressive barriers that IFN-γ has to overcome to eliminate tumors, and potential avenues for modulating the immune response in favor of tumor rejection.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IL-12; Immunosuppression; Immunotherapy; Interferon gamma; Tumor microenvironment

Mesh:

Substances:

Year:  2019        PMID: 31221552      PMCID: PMC7367502          DOI: 10.1016/j.smim.2019.05.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  200 in total

Review 1.  How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway.

Authors:  P R Wolf; H L Ploegh
Journal:  Annu Rev Cell Dev Biol       Date:  1995       Impact factor: 13.827

2.  Gamma interferon is able to enhance the oxidative metabolism of human neutrophils.

Authors:  G Berton; L Zeni; M A Cassatella; F Rossi
Journal:  Biochem Biophys Res Commun       Date:  1986-08-14       Impact factor: 3.575

3.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells.

Authors:  C Y Wu; C Demeure; M Kiniwa; M Gately; G Delespesse
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

6.  Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1.

Authors:  S Ito; P Ansari; M Sakatsume; H Dickensheets; N Vazquez; R P Donnelly; A C Larner; D S Finbloom
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

7.  Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines.

Authors:  T Kawamura; M Furue
Journal:  Eur J Immunol       Date:  1995-07       Impact factor: 5.532

8.  Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer.

Authors:  L T Vahdat; D J Cohen; D Zipin; K S Lo; D Donovan; D Savage; A Tiersten; G Nichols; A Troxel; C S Hesdorffer
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

9.  Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes.

Authors:  F Willems; A Marchant; J P Delville; C Gérard; A Delvaux; T Velu; M de Boer; M Goldman
Journal:  Eur J Immunol       Date:  1994-04       Impact factor: 5.532

10.  Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.

Authors:  J H Schiller; M Pugh; J M Kirkwood; D Karp; M Larson; E Borden
Journal:  Clin Cancer Res       Date:  1996-01       Impact factor: 12.531

View more
  36 in total

1.  Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma.

Authors:  Di-Guang Wen; Xiao-Ping Zhao; Yu You; Zuo-Jin Liu
Journal:  Cancer Immunol Immunother       Date:  2020-09-28       Impact factor: 6.968

Review 2.  Immune response and inflammation in cancer health disparities.

Authors:  Maeve Kiely; Brittany Lord; Stefan Ambs
Journal:  Trends Cancer       Date:  2021-12-27

Review 3.  The role of IFN-γ production during retroviral infections: an important cytokine involved in chronic inflammation and pathogenesis.

Authors:  Patrícia Azevedo Soares Cordeiro; Tatiane Assone; Gabriela Prates; Marcia Regina Martinez Tedeschi; Luiz Augusto Marcondes Fonseca; Jorge Casseb
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2022-09-30       Impact factor: 2.169

Review 4.  IFN-Aging: Coupling Aging With Interferon Response.

Authors:  Wei Cao
Journal:  Front Aging       Date:  2022-05-02

5.  Immunomodulatory Effects of Lepidium meyenii Walp. Polysaccharides on an Immunosuppression Model Induced by Cyclophosphamide.

Authors:  Wen-Ting Fei; Na Yue; Ai-Min Li; Shu-Hui Yu; Dan-Ping Zhao; Ying-Li Zhu; Chun Wang; Jian-Jun Zhang; Lin-Yuan Wang
Journal:  J Immunol Res       Date:  2022-07-04       Impact factor: 4.493

Review 6.  Drug Resistance in Colorectal Cancer: From Mechanism to Clinic.

Authors:  Qianyu Wang; Xiaofei Shen; Gang Chen; Junfeng Du
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

7.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

Review 8.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

9.  Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.

Authors:  Audrey Lequeux; Muhammad Zaeem Noman; Malina Xiao; Kris Van Moer; Meriem Hasmim; Alice Benoit; Manon Bosseler; Elodie Viry; Tsolere Arakelian; Guy Berchem; Salem Chouaib; Bassam Janji
Journal:  Oncogene       Date:  2021-06-21       Impact factor: 9.867

10.  Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy.

Authors:  Ana Luísa Correia; Joao C Guimaraes; Priska Auf der Maur; Duvini De Silva; Marcel P Trefny; Ryoko Okamoto; Sandro Bruno; Alexander Schmidt; Kirsten Mertz; Katrin Volkmann; Luigi Terracciano; Alfred Zippelius; Marcus Vetter; Christian Kurzeder; Walter Paul Weber; Mohamed Bentires-Alj
Journal:  Nature       Date:  2021-06-02       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.